

Benign Prostatic Hyperplasia (BPH) Drugs Industry Research Report 2023

<https://marketpublishers.com/r/B6C37E7186CBEN.html>

Date: August 2023

Pages: 96

Price: US\$ 2,950.00 (Single User License)

ID: B6C37E7186CBEN

Abstracts

This report aims to provide a comprehensive presentation of the global market for Benign Prostatic Hyperplasia (BPH) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Benign Prostatic Hyperplasia (BPH) Drugs.

The Benign Prostatic Hyperplasia (BPH) Drugs market size, estimations, and forecasts are provided in terms of sales volume (M Units) and revenue (\$ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Benign Prostatic Hyperplasia (BPH) Drugs market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Benign Prostatic Hyperplasia (BPH) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing.

This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2018-2023. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Eli Lilly

GlaxoSmithKline

Astellas Pharma

Sanofi

Pfizer

Abbott

Allergan

TEVA

Mylan

Novartis

Merck

Product Type Insights

Global markets are presented by Benign Prostatic Hyperplasia (BPH) Drugs type, along with growth forecasts through 2029. Estimates on sales and revenue are based on the price in the supply chain at which the Benign Prostatic Hyperplasia (BPH) Drugs are procured by the manufacturers.

This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).

Benign Prostatic Hyperplasia (BPH) Drugs segment by Type

Alpha-Blocker

Phosphodiesterase Type-5 Inhibitors

Others

Application Insights

This report has provided the market size (sales and revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).

This report also outlines the market trends of each segment and consumer behaviors impacting the Benign Prostatic Hyperplasia (BPH) Drugs market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Benign Prostatic Hyperplasia (BPH) Drugs market.

Benign Prostatic Hyperplasia (BPH) Drugs segment by Application

Hospitals

Drugstores

Others

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and

political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2018-2029.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2023 and forecast revenue for 2029.

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Benign Prostatic Hyperplasia (BPH) Drugs market scenario changed across the globe during the pandemic, post-pandemic

and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Benign Prostatic Hyperplasia (BPH) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of Benign Prostatic Hyperplasia (BPH) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Benign Prostatic Hyperplasia (BPH) Drugs industry.

This report helps stakeholders to gain insights into which regions to target globally

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Benign Prostatic Hyperplasia (BPH) Drugs.

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Benign Prostatic Hyperplasia (BPH) Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Benign Prostatic Hyperplasia (BPH) Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Benign Prostatic Hyperplasia (BPH) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

Contents

1 PREFACE

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 MARKET OVERVIEW

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
 - 2.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size (2018-2029) & (US\$ Million)
 - 2.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (2018-2029)
 - 2.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Average Price (2018-2029)
- 2.3 Benign Prostatic Hyperplasia (BPH) Drugs by Type
 - 2.3.1 Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US\$ Million)
 - 1.2.2 Alpha-Blocker
 - 1.2.3 Phosphodiesterase Type-5 Inhibitors
 - 1.2.4 Others
- 2.4 Benign Prostatic Hyperplasia (BPH) Drugs by Application
 - 2.4.1 Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US\$ Million)
 - 2.4.2 Hospitals
 - 2.4.3 Drugstores
 - 2.4.4 Others

3 MARKET COMPETITIVE LANDSCAPE BY MANUFACTURERS

- 3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Competitive Situation by Manufacturers (2018 Versus 2022)
- 3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) of Manufacturers (2018-2023)

3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue of Manufacturers (2018-2023)

3.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Manufacturers (2018-2023)

3.5 Global Benign Prostatic Hyperplasia (BPH) Drugs Industry Ranking, 2021 VS 2022 VS 2023

3.6 Global Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Manufacturing Sites & Headquarters

3.7 Global Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Product Type & Application

3.8 Global Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Date of Enter into This Industry

3.9 Global Benign Prostatic Hyperplasia (BPH) Drugs Market CR5 and HHI

3.10 Global Manufacturers Mergers & Acquisition

4 MANUFACTURERS PROFILED

4.1 Eli Lilly

4.1.1 Eli Lilly Company Information

4.1.2 Eli Lilly Business Overview

4.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2023)

4.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio

4.1.5 Eli Lilly Recent Developments

4.2 GlaxoSmithKline

4.2.1 GlaxoSmithKline Company Information

4.2.2 GlaxoSmithKline Business Overview

4.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2023)

4.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio

4.2.5 GlaxoSmithKline Recent Developments

4.3 Astellas Pharma

4.3.1 Astellas Pharma Company Information

4.3.2 Astellas Pharma Business Overview

4.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2023)

4.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio

4.3.5 Astellas Pharma Recent Developments

4.4 Sanofi

- 4.4.1 Sanofi Company Information
- 4.4.2 Sanofi Business Overview
- 4.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2023)
- 4.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
- 4.4.5 Sanofi Recent Developments
- 4.5 Pfizer
 - 4.5.1 Pfizer Company Information
 - 4.5.2 Pfizer Business Overview
 - 4.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2023)
 - 6.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
 - 6.5.5 Pfizer Recent Developments
- 4.6 Abbott
 - 4.6.1 Abbott Company Information
 - 4.6.2 Abbott Business Overview
 - 4.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2023)
 - 4.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
 - 4.6.5 Abbott Recent Developments
- 4.7 Allergan
 - 4.7.1 Allergan Company Information
 - 4.7.2 Allergan Business Overview
 - 4.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2023)
 - 4.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
 - 4.7.5 Allergan Recent Developments
- 6.8 TEVA
 - 4.8.1 TEVA Company Information
 - 4.8.2 TEVA Business Overview
 - 4.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2023)
 - 4.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
 - 4.8.5 TEVA Recent Developments
- 4.9 Mylan
 - 4.9.1 Mylan Company Information
 - 4.9.2 Mylan Business Overview
 - 4.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2023)

- 4.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
- 4.9.5 Mylan Recent Developments
- 4.10 Novartis
 - 4.10.1 Novartis Company Information
 - 4.10.2 Novartis Business Overview
 - 4.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2023)
 - 4.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
 - 4.10.5 Novartis Recent Developments
- 6.11 Merck
 - 6.11.1 Merck Company Information
 - 6.11.2 Merck Benign Prostatic Hyperplasia (BPH) Drugs Business Overview
 - 6.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2023)
 - 6.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
 - 6.11.5 Merck Recent Developments

5 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SCENARIO BY REGION

- 5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region: 2018 VS 2022 VS 2029
- 5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2018-2029
 - 5.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2018-2023
 - 5.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2024-2029
- 5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2018-2029
 - 5.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2018-2023
 - 5.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2024-2029
- 5.4 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
 - 5.4.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2018 VS 2022 VS 2029
 - 5.4.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2018-2029)
 - 5.4.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2018-2029)
 - 5.4.4 United States

5.4.5 Canada

5.5 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country

5.5.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2018 VS 2022 VS 2029

5.5.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2018-2029)

5.5.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2018-2029)

5.5.4 Germany

5.5.5 France

5.5.6 U.K.

5.5.7 Italy

5.5.8 Russia

5.6 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country

5.6.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2018 VS 2022 VS 2029

5.6.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2018-2029)

5.6.3 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2018-2029)

5.6.4 China

5.6.5 Japan

5.6.6 South Korea

5.6.7 India

5.6.8 Australia

5.6.9 China Taiwan

5.6.10 Indonesia

5.6.11 Thailand

5.6.12 Malaysia

5.7 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country

5.7.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2018 VS 2022 VS 2029

5.7.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2018-2029)

5.7.3 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2018-2029)

5.7.4 Mexico

5.7.5 Brazil

5.7.6 Argentina

5.8 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country

5.8.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country: 2018 VS 2022 VS 2029

5.8.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2018-2029)

5.8.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2018-2029)

5.8.4 Turkey

5.8.5 Saudi Arabia

5.8.6 UAE

6 SEGMENT BY TYPE

6.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2018-2029)

6.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2018-2029) & (M Units)

6.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2018-2029)

6.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2018-2029)

6.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2018-2029) & (US\$ Million)

6.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2018-2029)

6.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2018-2029)

7 SEGMENT BY APPLICATION

7.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2018-2029)

7.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2018-2029) & (M Units)

7.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2018-2029)

7.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2018-2029)

6.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2018-2029) & (US\$ Million)

6.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2018-2029)

7.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2018-2029)

8 VALUE CHAIN AND SALES CHANNELS ANALYSIS OF THE MARKET

8.1 Benign Prostatic Hyperplasia (BPH) Drugs Value Chain Analysis

8.1.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials

8.1.2 Raw Materials Key Suppliers

8.1.3 Benign Prostatic Hyperplasia (BPH) Drugs Production Mode & Process

8.2 Benign Prostatic Hyperplasia (BPH) Drugs Sales Channels Analysis

8.2.1 Direct Comparison with Distribution Share

8.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors

8.2.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers

9 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS ANALYZING MARKET DYNAMICS

9.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends

9.2 Benign Prostatic Hyperplasia (BPH) Drugs Industry Drivers

9.3 Benign Prostatic Hyperplasia (BPH) Drugs Industry Opportunities and Challenges

9.4 Benign Prostatic Hyperplasia (BPH) Drugs Industry Restraints

10 REPORT CONCLUSION

11 DISCLAIMER

I would like to order

Product name: Benign Prostatic Hyperplasia (BPH) Drugs Industry Research Report 2023

Product link: <https://marketpublishers.com/r/B6C37E7186CBEN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B6C37E7186CBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970